Monte Rosa Therapeutics, Inc. GLUE
We take great care to ensure that the data presented and summarized in this overview for Monte Rosa Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GLUE
View all-
Nea Management Company, LLC Timonium, MD7.69MShares$92.2 Million2.88% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.33MShares$75.8 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA5.66MShares$67.9 Million1.0% of portfolio
-
Versant Venture Management, LLC San Francisco, CA5.65MShares$67.8 Million45.25% of portfolio
-
Baker Bros. Advisors LP New York, NY4.92MShares$58.9 Million0.22% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.73MShares$44.7 Million0.31% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.36MShares$40.3 Million0.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.14MShares$37.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.36MShares$28.3 Million0.0% of portfolio
-
Aisling Capital Management LP New York, NY1.47MShares$17.7 Million1.85% of portfolio
Latest Institutional Activity in GLUE
Top Purchases
Top Sells
About GLUE
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Insider Transactions at GLUE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 03
2025
|
Edmund Dunn Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,062
-7.99%
|
$8,248
$4.45 P/Share
|
|
Mar 24
2025
|
Chandra P. Leo |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$50,000
$5.84 P/Share
|
|
Jan 02
2025
|
Sharon Townson Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,000
+50.0%
|
-
|
|
Jan 02
2025
|
Markus Warmuth President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
128,000
+19.03%
|
-
|
|
Jan 02
2025
|
Jennifer Champoux Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|
|
Jan 02
2025
|
Filip Janku Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,000
+44.34%
|
-
|
|
Jan 02
2025
|
Edmund Dunn Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,850
+31.48%
|
-
|
|
Jan 02
2025
|
Philip Nickson Chief Business & Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,000
+50.0%
|
-
|
|
Oct 29
2024
|
Versant Venture Capital Vi, L.P. |
SELL
Open market or private sale
|
Indirect |
67,905
-2.08%
|
$611,145
$9.25 P/Share
|
|
Oct 28
2024
|
Versant Venture Capital Vi, L.P. |
SELL
Other acquisition or disposition
|
Indirect |
415,535
-83.65%
|
-
|
|
Oct 28
2024
|
Versant Venture Capital Vi, L.P. |
BUY
Other acquisition or disposition
|
Indirect |
48,945
+50.0%
|
-
|
|
Oct 28
2024
|
Versant Venture Capital Vi, L.P. |
SELL
Other acquisition or disposition
|
Direct |
1,019,867
-20.0%
|
-
|
|
Oct 28
2024
|
Versant Venture Capital Vi, L.P. |
SELL
Open market or private sale
|
Indirect |
89,990
-4.29%
|
$809,910
$9.66 P/Share
|
|
Sep 20
2024
|
Versant Venture Capital Vi, L.P. |
SELL
Open market or private sale
|
Direct |
1,132,566
-18.17%
|
$6,795,396
$6.53 P/Share
|
|
Sep 13
2024
|
Versant Venture Capital Vi, L.P. |
SELL
Open market or private sale
|
Direct |
9,269
-0.15%
|
$55,614
$6.16 P/Share
|
|
Sep 12
2024
|
Versant Venture Capital Vi, L.P. |
SELL
Open market or private sale
|
Direct |
16,047
-0.26%
|
$96,282
$6.0 P/Share
|
|
Sep 11
2024
|
Versant Venture Capital Vi, L.P. |
SELL
Open market or private sale
|
Direct |
541,897
-7.97%
|
$3,251,382
$6.0 P/Share
|
|
Jul 05
2024
|
Edmund Dunn Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,610
-10.35%
|
$4,830
$3.83 P/Share
|
|
Jun 03
2024
|
Edmund Dunn Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,207
-7.2%
|
$4,828
$4.04 P/Share
|
|
Jun 28
2021
|
Versant Venture Capital Vi, L.P. |
BUY
Open market or private purchase
|
Indirect |
157,895
+7.0%
|
$3,000,005
$19.0 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 278K shares |
|---|---|
| Open market or private purchase | 10K shares |
| Open market or private sale | 2.06K shares |
|---|